Tenofovir amibufenamide shows efficacy in chronic hepatitis B patients with normal ALT
View as a Web Page
News Medical
 
  Hepatology Hepatology logo  
  The latest hepatology news from News Medical  
 Towards fully automated artificial pancreas systems for better diabetes careTowards fully automated artificial pancreas systems for better diabetes care
 
Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review of the technology.
 
 
 Tenofovir amibufenamide shows efficacy in chronic hepatitis B patients with normal ALTTenofovir amibufenamide shows efficacy in chronic hepatitis B patients with normal ALT
 
Chronic hepatitis B virus (HBV)-infected patients may exhibit liver fibrosis and other pathological changes despite normal alanine aminotransferase (ALT).
 
   Microbial DNA signature in the blood differentiates primary liver cancer from metastatic colorectal cancerMicrobial DNA signature in the blood differentiates primary liver cancer from metastatic colorectal cancer
 
Determining whether a cancerous tumor originated in a given location or spread there from another tissue or organ in the body is important when assessing the likely course of a patient's disease.
 
   CHI3L1 emerges as a powerful biomarker for liver disease diagnosis and managementCHI3L1 emerges as a powerful biomarker for liver disease diagnosis and management
 
The identification of Chitinase-3-like protein 1 (CHI3L1) as a crucial biomarker in liver disease is revolutionizing how clinicians approach the diagnosis, monitoring, and treatment of various liver conditions.
 
   ATOX1 drives hepatocellular carcinoma progression through c-Myb and PI3K/AKT activationATOX1 drives hepatocellular carcinoma progression through c-Myb and PI3K/AKT activation
 
Despite advancements in diagnostic and therapeutic strategies, hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality.
 
 Family history of liver disease significantly raises risk of severe alcohol-related hepatitis
 
Family history of liver disease significantly raises risk of severe alcohol-related hepatitisIn a groundbreaking study, research scientists from the Indiana University School of Medicine and Regenstrief Institute found that individuals with a parent who died from liver disease face more than double the risk of developing alcohol-associated hepatitis, one of the deadliest forms of alcohol-related liver disease, compared with similar heavy drinkers without that family history.
 
 
 Targeting gut signaling protein may protect against alcohol-related liver damage
 
Targeting gut signaling protein may protect against alcohol-related liver damageAlcohol-associated liver disease (ALD) is a major cause of liver transplantation and death worldwide, and its impact is only growing. In 2022, the annual cost of ALD in the United States was $31 billion.
 
 
 New formulation of chemotherapy drug opens doors to advanced cancer treatment options
 
University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than standard forms of chemotherapy.
 
 
 Dementia-like protein clumping found in early pancreatic cancer cells
 
Cancer Research UK-funded scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer. The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney | Boston

Copyright © 2000-2025